Screener
Arcus Biosciences RCUS Debt Issuance Proceeds
Debt Issuance Proceeds at other companies
Other financials
Where this comes from
Reported directly by Arcus Biosciences in its filing.
Tagged under the XBRL concept us-gaap:ProceedsFromIssuanceOfDebt.
The source filing: Arcus Biosciences’s 10-K, filed February 25, 2026.
- Filed
- Feb 25, 2026, 4:11 PM EST
- Fiscal year
- FY2025
- Accession
- 0001724521-26-000009
| Line item | Year Ended December 31, 2025 | Year Ended December 31, 2024 | Year Ended December 31, 2023 |
|---|---|---|---|
| Net cash provided by (used in) investing activities | 66 | (84) | 194 |
| Cash flow from financing activities | |||
| Proceeds from issuance of common stock ($14, $228 and $20 from a related party), net | 429 | 228 | 25 |
| Proceeds from debt issuances, net | 49 | 47 | — |
| Proceeds from issuance of common stock pursuant to equity award plans | 10 | 9 | 8 |
| Payments of employee taxes related to net settlement of equity awards | — | (7) | — |
| Net cash provided by financing activities | 488 | 277 | 33 |
| Net increase (decrease) in cash, cash equivalents and restricted cash | 72 | 23 | (79) |
Item 8. Financial Statements and Supplementary Data
FAQ
- What is Arcus Biosciences's debt issuance proceeds?
- Arcus Biosciences (RCUS) reported debt issuance proceeds of $12.25M in Q4 2025.
- What does debt issuance proceeds mean?
- Cash received from issuing bonds, notes, term loans, and other debt instruments in the capital markets or from bank lending.
Ask your AI about Arcus Biosciences's debt issuance proceeds.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude